Yonathan Lissanu

This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.

This study shows that SMARCA4 mutations in lung cancer disrupt enhancer landscapes and innate immune gene expression, leading to immunotherapy resistance.

The paper identifies ERBB2 alterations as a recurrent oncogene in esophageal adenocarcinoma brain metastases and links them to monoclonal seeding and treatment response.

This study shows that disrupting the WRAD core in pancreatic cancer leads to DNA replication errors, immune response activation, and improved response to immune checkpoint inhibitors.

This study identifies ROCK inhibition as a strategy to overcome metabolic adaptation in cancer cells to OXPHOS inhibition, showing synergistic anti-tumor effects.

The paper establishes a database of lung cancer mouse models to improve data comparison and translational relevance by aligning mouse mutations with human lung cancer mutations.